ReflexMD review

ReflexMD is worth comparing for a clearly labeled compounded prescription pathway, but the assigned clinical practice, dispensing pharmacy and full continuing quote remain unresolved. Its two-day cancellation rule requires planning, and the published nonrefundable-fee terms make written clarification of any clinical-denial exception important before payment.

ReflexMD is a telehealth coordination platform operated by ReflexMD, Inc., rather than the organization automatically responsible for medical treatment. Its terms describe independent medical groups and providers who make prescribing decisions. That distinction matters when deciding where to direct a clinical question, request records or resolve a prescription problem. A linked notice names MD Integrations, Inc. doing business as MD Integrations, which provides a concrete identity in the privacy paperwork. It does not establish that this is the legal practice assigned to every patient. Ask for that practice’s name and the treating clinician’s details before enrollment. Our assessment concerns the public offer and contract disclosures, rather than firsthand treatment or independent credential verification. The program can be considered for a prescription consultation, but its website alone cannot tell an individual whether treatment is appropriate, available in their state or supported by a particular pharmacy. The platform privacy policy distinguishes account and transaction information from protected clinical information and says ReflexMD itself is not a HIPAA covered entity, although obligations can depend on its role. A medical intake does not mean every website interaction receives the same protections as a medical record. Review the platform policy alongside the treating practice’s notice before deciding what to share.

The described route involves a health-history assessment, a clinician’s decision and pharmacy fulfillment if a prescription is issued. The terms describe a network-pharmacy arrangement, but the pharmacy assigned to a particular order is not established. Ask who will dispense the medicine, where to obtain its contact information and whether any requested alternative changes the price or supply. The terms require an adult applicant in a supported location. General marketing about physicians in every state does not establish that every medication can be prescribed and shipped in every state. A complete product-specific state list or universal numerical BMI threshold was not established. Confirm location eligibility before authorizing recurring payment. The fulfillment policy describes three to six business days for pharmacy processing, followed by overnight shipment. This is an estimate rather than a guaranteed arrival date. A person transferring care should coordinate records and instructions with the treating clinician rather than use a marketing delivery estimate as a treatment schedule. The telehealth consent explains that remote assessment may provide insufficient information and that an in-person or alternative evaluation may be necessary. It also gives a practical records route: patients can request that their telehealth record be sent to another provider by emailing support with consent and the receiving provider’s contact details. Arrange that continuity before ending an existing care relationship.

The homepage advertises compounded semaglutide at $297 per month, compounded tirzepatide at $367 and generic oral weight-control tablets at $199. It separately promotes 15% off three-month plans with FALLRESET15. Those product cards do not establish the dose, supply or exact first and renewal debit for a selected plan. ReflexMD’s published terms allow monthly and three-month subscription periods and say medication and pharmacy fulfillment are included. The initial payment is associated with the day of provider review. The selected plan’s total, dose coverage and next charge still need confirmation before payment. A page describing a month-to-month service sits alongside terms that accommodate three-month billing, so it is especially important to distinguish a monthly equivalent from an actual monthly debit. Do not assume a short promotional discount continues at renewal. The published amounts do not establish a complete continuing bill for a specific dose and supply. The practical comparison is the whole authorized charge for the proposed supply, including any commitment, rather than a product card in isolation. Cancellation has a specific deadline: request it at least two days before the applicable renewal processing date. Non-California residents are told to call (866) 849-6382; California residents may call or use the support email listed in its terms. Save the request and confirmation, and ask which future shipment and charge the cancellation stops. The fulfillment policy says already-paid monthly fees are not refundable. The applicable terms should also specify what happens if the clinician declines treatment. The general paid-fee policy does not establish a full clinical-denial refund, so obtain any exception, amount and timing in writing. Clinical denial, cancellation before the next renewal and an approved patient changing their mind are different events; do not assume the same refund applies to each. Save the selected checkout terms and any written clarification before authorizing payment.

The program explicitly markets compounded semaglutide and compounded tirzepatide. A compounded preparation should not be presented as an FDA-approved branded product, and brand-drug results do not establish the performance of an individual pharmacy’s preparation. Ask the clinician and dispensing pharmacy for the exact active ingredient, concentration, prescribed dose, quantity, storage requirements and beyond-use information. Those details determine what is actually being supplied and prevent an advertised monthly price from obscuring different quantities or strengths. ReflexMD has also advertised oral weight-control tablets, but that generic wording does not establish oral semaglutide, an approved GLP-1 tablet or even the active ingredient. We therefore do not classify that card as an oral GLP-1 offer. Anyone specifically seeking a tablet should obtain its ingredient and regulatory status first and compare it with product-specific oral options. The public pages reviewed did not identify the dispensing pharmacy assigned to a particular order. The network-pharmacy terms and a medical privacy notice help explain parts of the arrangement, but neither substitutes for the actual prescription label, practice identity or individualized counseling.